Cecilia Brown

DocwireNews

Osimertinib following definitive chemoradiotherapy (CRT) showed a statistically significant and “clinically meaningful” improvement in progression-free survival (PFS) for patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC), according to results from the phase 3 LAURA trial.
The results of the study establish osimertinib as the new standard of care for EGFR-mutated NSCLC in this setting, according to the study authors, led by Suresh S. Ramalingam, MD, FACP, FASCO, of the Winship Cancer Institute at Emory University. Dr. Ramalingam presented primary results from the trial during a plenary session held at the 2024 American Society of Clinical Oncology Annual Meeting.
Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor with activity in the central nervous system, is currently recommended for EGFR-mutated advanced/metastatic NSCLC and as an adjuvant therapy for resectable EGFR-mutated NSCLC, according to the study investigators. However, the “benefit of consolidation immunotherapy specifically for EGFR-[mutated] NSCLC remains uncertain, with limited data available,” Dr. Ramalingam and colleagues explained.
LAURA, a double-blinded and placebo-controlled phase 3 trial, assessed the efficacy and safety of osimertinib in adults with unresectable stage III EGFR-mutated (Ex19del/L858R) NSCLC who received definitive platinum-based concurrent CRT/sequential CRT and did not have progression. The patients had a World Health Organization performance status of 0 or 1.
The investigators randomized 216 patients 2:1 to receive osimertinib 80 mg (n=143) or placebo (n=73) once a day until progression, as confirmed by a blinded independent central review (BICR), or discontinuation. The researchers stratified patients by multiple characteristics, including if they had received concurrent versus sequential CRT, had stage IIIA disease versus stage IIIB/IIIC, and if they were Chinese or not Chinese. The baseline characteristics were “generally balanced” between the study arms, with similar proportions of female patients and stage IIIA, IIIB, IIIC, and Ex19del disease in each arm.
The study mandated imaging, including brain magnetic resonance imaging, at baseline, then every 8 weeks until week 48, and then every 12 weeks until progression per BICR. Patients were offered open-label osimertinib after progression was confirmed. The primary end point of the study was PFS, as assessed by BICR. Secondary end points included overall survival (OS) and safety. The data cutoff was January 5, 2024.
The study showed that osimertinib significantly improved PFS per BICR compared with placebo (hazard ratio [HR], 0.16; P&lt;.001). The median PFS was 39.1 months in patients receiving osimertinib (95% CI, 31.5 to not calculable) and 5.6 months for those receiving placebo (95% CI, 3.7-7.5). The 12-month PFS rate was 74% in patients receiving osimertinib, nearly 3 times higher than the rate of 22% in those receiving placebo. The 24-month PFS rate was 65% in patients receiving osimertinib and 13% in those receiving placebo.
The “PFS benefit was consistent across predefined subgroups,” according to the study investigators. An interim OS analysis, with 20% maturity, has shown a “trend in favor” of osimertinib (HR, 0.81; P=.530). Among the patients receiving placebo, 81% received osimertinib after progression.
All-causality adverse events (AEs) were reported in 98% of patients receiving osimertinib and in 88% receiving placebo. AEs of grade ≥3 occurred in 35% of patients receiving osimertinib and in 12% of those receiving placebo. Serious AEs occurred in 38% and 15%, respectively. Radiation pneumonitis AEs occurred in 48% receiving osimertinib and in 38% receiving placebo, with the majority being grade 1 or 2. Any AEs leading to discontinuation were reported in 13% of those receiving osimertinib and in 5% of those receiving placebo.
“[Osimertinib] after definitive CRT demonstrated a statistically significant and clinically meaningful improvement in PFS for unresectable [stage] III EGFR-[mutated] NSCLC, with no unexpected safety signals,” Dr. Ramalingam and colleagues concluded, noting that the study establishes osimertinib as the new standard of care for EGFR-mutated NSCLC in this setting.
Reference
Ramalingam S, Kato T, Dong X, et al. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: primary results of the phase 3 LAURA study. Presented at the 2024 American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2024; Chicago, Illinois.

Jordana Jampel

Examining the Gut-Brain Axis, Neurotrophic Dysfunction Association With Crohn Disease

Gastroenterology

Genomic Architecture of Varying Phenotypic Heart Shapes and Association With Cardiovascular Disease Risk

Preventive Cardiology

Kimmie Ng, MD, MPH

Dr. Kimmie Ng: From Concert Pianist Aspirations to Pioneering GI Cancer Research and Patient Care

GI Cancer

Latest News

Phase 3 LAURA Trial Plenary Presentation Receives Standing Ovation

ASCO 2024: Focus on Lung Cancer

The results of the study establish osimertinib as the new standard of care for EGFR-mutated NSCLC in this setting, according to the study authors.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe